Herpes Zoster as a Marker of Occult Malignancy in Older Adults: A Real-World Cohort Study

Lung, Respiratory and Thoracic Cancer

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

Lung Cancer

Gomez-Randulfe I, Monaca F, Cantale O, Reale ML, Mrak L, Zullo L, Diaz SS, Bueno MZ, Maridueña Moreno MA, Davis C, Cox S, Lee D, Shah R, Geldart T, Baena J, Benitez JC, Rosario Garcia Campelo MA, Remon J, Planchard D, Galetta D, Tiseo M, Cortinovis D, Metro G, Bria E, Passiglia F, Novello S, Califano R

doi: 10.1016/j.lungcan.2025.108797

Leukemia

Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study

Br J Haematol

Costa A, Scalzulli E, Carmosino I, Bisegna ML, Laganà A, Ielo C, Cappelli L, Martelli M, Breccia M

doi: 10.1111/bjh.70418

Multiple Myeloma (MM)

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Clin Cancer Res

Suvannasankha A, Li M, Omofuma O, Hampp C, Phelan M, Breskin A, Shao P, Roccia T, Mukherjee N, Shrestha A, Lee D, Glass J, Kroog GS, Rodriguez Lorenc K

doi: 10.1158/1078-0432.CCR-25-4068

Leukemia

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study

Am J Hematol

Aspas Requena G, Montesinos P, Bérard E, Bertoli S, Rodríguez-Veiga R, Simand C, Torres L, Peterlin P, Tormo M, Birsen R, Bergua-Burgues JM, Tavernier E, Bernal Del Castillo T, Carré M, Gil C, Contejean A, Rodríguez-Arbolí E, Orvain C, Rodríguez-Medina C, Veronese L, Sayas Lloris MJ, Delabesse E, Serrano J, Mineur A, García-Fortes M, Guieze R, Amigo ML, Pigneux A, Algarra Algarra L, Recher C, Dumas PY, Martínez-Cuadrón D

doi: 10.1002/ajh.70233

Further Publications

Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study

Adv Ther

van der Vorst MJDL, Maximiano Alonso C, Calderón Boyle TA, Schilder JM, Malinowska IA, Ye G, Kroep JR, Mañé Martínez JM, Kuplast J, Perhanidis J, Evans C, Golembesky AK, Tasca G, Kommoss S

doi: 10.1007/s12325-026-03600-9

Leukemia

Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study

Leuk Lymphoma

Bronstein Y, Rokach L, Herishanu Y, Arbel R, Razi T, Nachmias N

doi: 10.1080/10428194.2026.2711592

Non-Malignant Blood Disorders

Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real-world study in Quebec

Br J Haematol

Girard A, Charette L, Haouchine M, Bozec L, Bouyadjera MZB, Poitras M, Taillefer VT, Trudeau C, Pastore Y, Letarte N, Forté S

doi: 10.1111/bjh.70622

Leukemia

Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

Am J Hematol

Aspas Requena G, Rodríguez-Veiga R, Gil C, Botella C, Aguiar E, Trigo F, Colorado M, Del Bernal Del Castillo T, Barragan E, Tormo M, Rodríguez Arbolí E, Serrano López J, García Boyero R, Castaño T, Herrera Puente P, Romero Riquelme MA, Sayas Lloris MJ, Algarra-Algarra L, Rodriguez-Medina C, Sossa Melo CL, Labrador Gomez J, Vives S, Salamero O, Amigo ML, Valero Nuñez M, Rojas C, Bass F, García-Fortes M, Vidriales Vicente B, Polo M, Benavente C, Madrigal MD, Espinoza M, Pérez-Encinas M, Amador Barciela ML, Bautista G, Solana-Altabella A, Cano-Ferri I, Colmenares R, García-Ramírez P, Ibáñez Alis F, Barrios García M, Rodríguez-Macías G, López M, Oliva Hernández AY, Cerveró CJ, Martínez-Cuadrón D, Chorão P, Bergua Burgues JM, Montesinos P

doi: 10.1002/ajh.70340

Leukemia

Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009-2019: A Real-World Study From the UK's Haematological Malignancy Research Network

Int J Cancer

Kane E, Smith A, Howell D, Cargo C, Rothwell K, Green S, Patmore R, Roman E

doi: 10.1002/ijc.70518

Related content

Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study

Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study

Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study

Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study

Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real-world study in Quebec

Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009-2019: A Real-World Study From the UK's Haematological Malignancy Research Network